title: Promising growth and investment in the cell therapy industry during the first quarter of 2012.
abstract: In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.
authors.affiliation: The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK.
authors.forename: David A
authors.initials: DA
authors.lastname: Brindley
authors.forename: Natasha L
authors.initials: NL
authors.lastname: Davie
authors.forename: William A
authors.initials: WA
authors.lastname: Sahlman
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Bonfiglio
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Culme-Seymour
authors.forename: Brock C
authors.initials: BC
authors.lastname: Reeve
authors.forename: Chris
authors.initials: C
authors.lastname: Mason
mesh_terms: D017690:Cell Transplantation / Q000191:economics* / Q000639:trends*; D019981:Health Care Sector; D006801:Humans; D007449:Investments; D014481:United States